Catalog No.
Product Name
Application
Product Information
Citations
-
P38 MAPK Inhibitor
NJK14047 is a selective inhibitor of p38 MAPK, a key signaling pathway involved in inflammatory responses. This compound effectively inhibits the differentiation of naive T-cells into Th1 and Th17 cells, thus modulating immune responses. NJK14047 has demonstrated therapeutic potential in preclinical models, ameliorating collagen-induced rheumatoid arthritis and imiquimod-induced psoriasis in mice, making it a valuable tool for research into inflammatory diseases and immune regulation. -
p38 Inhibitor
p38-α MAPK-IN-10 is a potent inhibitor of p38α MAPK, exhibiting an IC50 value of 4 nM. This compound is utilized in research to investigate the role of p38α in inflammatory processes, cellular stress responses, and various pathological conditions. Its selective inhibition makes it an essential tool for studying signal transduction pathways and developing potential therapeutic strategies. -
p38 MAPK Inhibitor Negative Control
SB 202474 is a negative control compound designed for p38 MAPK inhibition studies. Unlike its active analog SB203580, SB 202474 does not inhibit p38 MAPK activity, making it an essential tool for validating experimental results in MAPK pathways. Additionally, it has been shown to suppress melanin synthesis induction, providing further applications in biochemical research related to pigment production. -
p38 Inhibitor
p38 Kinase Inhibitor 7 is a potent inhibitor of p38α with an IC50 value of 5.25 nM. This compound effectively reduces TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM. p38 Kinase Inhibitor 7 is valuable for research focused on inflammation and related signaling pathways, making it a useful tool in cytokine modulation studies. -
p38 MAPK Inhibitor
SB-204900 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound exhibits significant inhibition of p38 MAPK phosphorylation, making it a valuable tool in the study of inflammatory signaling pathways. SB-204900 is primarily utilized in research focused on understanding the molecular mechanisms underlying inflammatory responses and developing potential therapeutic strategies for related conditions. -
p38α Inhibitor
FS-694 is a potent inhibitor of p38α, exhibiting an IC50 of 0.2 nM. This compound effectively suppresses TNFα release in human whole blood, with an IC50 value of 35.0 nM. FS-694 can be utilized in research aimed at understanding p38α signaling pathways and investigating inflammatory responses. -
p38 MAP Kinase Inhibitor
SC-68376 is a selective, reversible inhibitor of p38 MAP kinase, functioning through competitive inhibition of ATP binding. This compound exhibits significant biological activity in modulating inflammatory responses and cellular stress signaling pathways. SC-68376 is valuable for research applications related to inflammation, neurodegenerative diseases, and cancer, enabling the exploration of p38 MAP kinase's role in various pathological conditions. -
p38-α MAPK Inhibitor
p38-α MAPK-IN-9 is a highly potent inhibitor of the p38-α mitogen-activated protein kinase (MAPK), exhibiting a Ki value of 0.057 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNFα) production in human peripheral blood mononuclear cells (hPBMCs), with an IC50 of 18 nM. p38-α MAPK-IN-9 is valuable for research applications focused on inflammatory signaling pathways and the study of cytokine modulation. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor VI is a selective inhibitor of p38 MAPK, exhibiting a moderate inhibition rate of 24%. This compound is instrumental in research focused on inflammation, apoptosis, and cellular stress responses. It can be utilized to explore the role of p38 MAPK in various pathological conditions and to develop therapeutic strategies targeting this signaling pathway. -
p38 Inhibitor
p38 MAP Kinase-IN-1 is a selective inhibitor of the p38 MAP kinase pathway, which plays a crucial role in mediating inflammation and immune responses. This compound is valuable for researchers investigating the mechanisms behind inflammatory diseases and autoimmune disorders. It can facilitate studies aimed at understanding p38's role in cellular signaling and its potential as a therapeutic target in inflammatory-related conditions. -
p38 MAPK Inhibitor
p38 MAPK-IN-6 is a selective p38 MAPK inhibitor that exhibits potential in modulating inflammatory pathways and stress responses. With a demonstrated inhibitory effect of 14% at a concentration of 10 μM, this compound serves as a valuable tool for studying p38 MAPK signaling in various cellular models. Its application extends to research in conditions associated with chronic inflammation and related diseases. -
p38 MAPK Inhibitor
AKP-001 is a selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). This compound effectively reduces the production of pro-inflammatory cytokines, making it valuable for studying inflammatory processes. AKP-001 is particularly relevant for research focused on rheumatoid arthritis and inflammatory bowel disease, providing insights into potential therapeutic interventions for these conditions. -
BRD 4/p38α/BRDT Inhibitor
SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways. -
p38 MAPK Activator
OVA-E1 peptide is an activator of p38 MAPK, derived from the original SIINFEKL sequence (OVA 257-264). This peptide effectively stimulates both p38 and JNK signaling pathways in both mutant and wild-type thymocytes. It serves as a valuable tool for studying MAPK pathways and their roles in cellular responses such as inflammation and stress signaling in various research applications. -
p38 MAPK Inhibitor, JNK Inhibitor
HE4-1 leech peptide is a selective inhibitor of p38 MAPK and c-Jun N-terminal kinase (JNK). It effectively suppresses macrophage migration while maintaining normal macrophage immunological functions, such as phagocytosis, lysozyme activity, and the expression of various inflammatory factors. This peptide is primarily utilized in research focused on atherosclerosis and inflammation-related studies. -
TOPK-p38/JNK Inhibitor
TOPK-p38/JNK-IN-1 is an orally active inhibitor targeting the TOPK-p38/JNK signaling pathway, exhibiting an IC50 value of 2.14 µM for nitric oxide production. This compound demonstrates significant anti-inflammatory activity by inhibiting the phosphorylation of downstream proteins while preventing degradation of TOPK. Research applications include studies on inflammatory processes and cellular signaling mechanisms in various disease models. -
JNK3/p38 Inhibitor
SR-3737 is a potent inhibitor of JNK3 and p38 mitogen-activated protein kinases, with IC50 values of 12 nM and 3 nM, respectively. This compound exhibits significant biological activity by modulating pathways involved in stress responses and inflammation. SR-3737 is useful in research applications focusing on neuronal signaling, cytokine production, and the molecular mechanisms underlying various neurodegenerative diseases. -
p38 Inhibitor
p38 Kinase Inhibitor 8 is a selective inhibitor of p38β and JNK2α2, demonstrating IC50 values of 6.3 nM and 53.6 nM, respectively. This compound has shown significant anti-inflammatory properties in models of collagen-induced arthritis in rats, making it a valuable tool for research into inflammatory diseases and related signaling pathways. Its orally active nature enhances its practicality for in vivo studies. -
p38 MAPK Inhibitor
Gossypetin is a hexahydroxylated flavonoid that primarily targets the p38 MAPK signaling pathway by inhibiting mitogen-activated protein kinase kinases MKK3 and MKK6. This inhibition effectively attenuates the MKK3/6-p38 signaling pathway, leading to multiple pharmacological effects, including antioxidant, antibacterial, and anticancer activities. Gossypetin is of interest in research exploring therapeutic applications against various diseases mediated by p38 MAPK signaling dysregulation. -
p38 Inhibitor
N-Acetylmuramic acid is a key component of the bacterial cell wall peptidoglycan, targeting the p38 MAPK signaling pathway. It plays a critical role in maintaining cell shape and integrity in bacterial species, particularly Bacteroides forsythus, while also inhibiting spore germination through the inhibition of hexosaminidase and core enzymes. Additionally, N-acetylmuramic acid exhibits significant anti-inflammatory activity, making it a valuable reagent in studies of cellular proliferation and inflammatory responses. This compound is noted for its oral bioactivity. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
p38 MAPK Inhibitor
Bisabolangelone is a potent inhibitor of the p38 MAPK pathway. Isolated from the roots of Osterici Radix, this sesquiterpene derivative demonstrates significant anti-inflammatory activity by inhibiting LPS-stimulated inflammation through the blockade of the NF-kappaB and MAPK signaling pathways in macrophages. Additionally, Bisabolangelone exhibits anti-ulcer activities, making it a valuable tool in studies related to inflammation and gastrointestinal disorders. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor III is a potent inhibitor of p38 MAPK, with an IC50 value of 0.9 μM. This compound also effectively reduces the release of pro-inflammatory cytokines, specifically IL-1β and TNF-α, with IC50 values of 0.37 μM and 0.044 μM, respectively. p38 MAP Kinase Inhibitor III is valuable for research in inflammation, signaling pathways, and related therapeutic applications. -
p38α Inhibitor
Emprumapimod is a selective inhibitor of p38α MAPK that exhibits potent oral activity. By directly inhibiting LPS-induced IL-6 production in RPMI-8226 cells (IC50=100 pM), it presents significant anti-inflammatory properties. This compound is applicable in research studies focused on dilated cardiomyopathy and acute inflammatory pain, making it a valuable tool for elucidating the role of p38α in various inflammatory conditions. -
p38α MAPK Inhibitor
p38α Inhibitor 2 is a highly selective inhibitor of the p38α mitogen-activated protein kinase (MAPK), exhibiting a pIC50 value of 9.6. This compound demonstrates potent inhibition of the hERG ion channel with an IC50 of 27 μM. Additionally, p38α Inhibitor 2 shows an excellent selectivity profile, demonstrating less than 30% inhibition across a panel of 51 protein kinases at a concentration of 10 μM, indicating its potential utility in various biological research applications focused on inflammation and stress responses. -
p38α Inhibitor
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, exhibiting an IC50 of 3.2 nM. This compound also demonstrates weak inhibition of p38β MAPK with an IC50 of 122 nM. SD-169 has been shown to impede the development and progression of diabetes by inhibiting T cell infiltration and activation, making it valuable for research in immunology and metabolic disease pathways. -
p38 MAPK Inhibitor
p38 MAPK-IN-4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK) with an IC50 of 35 nM. This compound modulates the p38 MAPK signaling pathway, which is critical in cellular responses to stress and inflammation. It is suitable for research applications investigating inflammatory diseases, cancer, and other conditions associated with p38 MAPK activity. -
Anti-inflammatory/Anti-fibrotic Agent
GDC-3280 is an orally active anti-inflammatory and anti-fibrotic agent that operates primarily through the inhibition of the ASK1-p38 MAPK pathway. It effectively mitigates the inflammatory and fibrotic responses associated with silicosis and influences macrophage polarization. GDC-3280 is a valuable tool for research aimed at understanding and developing therapeutic strategies for inflammatory and fibrotic diseases. -
p38α MAPK Inhibitor
p38 MAP Kinase Inhibitor IV is a selective ATP-competitive inhibitor targeting p38α MAPK, exhibiting IC50 values of 0.13 μM and 0.55 μM for p38α and p38β MAPK, respectively. This compound plays a crucial role in modulating cellular responses to stress and inflammation by inhibiting the p38 MAPK signaling pathway. It is utilized in research applications focused on therapeutic interventions for inflammatory diseases and various cancer models. -
p38 MAPK Inhibitor, coumarin, glucoside
Esculin sesquihydrate is a coumarin glucoside that serves as an inhibitor of p38 MAPK. This compound has demonstrated significant biological activity in ameliorating cognitive impairment associated with experimental diabetic nephropathy. Additionally, esculin sesquihydrate exhibits antioxidant and anti-inflammatory properties, primarily through modulation of the MAPK signaling pathway, making it valuable for research in diabetes-related complications and inflammation studies. -
p38α/β Degrader
NR-7h is a selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM and 27.2 nM for p38α in T47D and MB-MDA-231 cells, respectively. This compound effectively induces degradation of these kinases, facilitating the study of their roles in cellular signaling pathways. NR-7h is applicable in cancer research and other studies investigating inflammatory responses and signal transduction mechanisms. -
p38 MAPK Inhibitor
PF-03715455 is a selective p38 MAPK inhibitor with significant potency, demonstrating IC50 values of 0.88 nM for p38α and 23 nM for p38β. This compound effectively inhibits LPS-induced TNFα production in human whole blood, with an IC50 of 1.7 nM. PF-03715455 has potential applications in research focusing on chronic obstructive pulmonary disease (COPD) and inflammation-related pathways. -
DDR/p38 Inhibitor
SR-302 is a selective DDR/p38 inhibitor that exhibits potent biological activity with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. This compound is valuable for investigating fibrotic disorders, including renal and pulmonary fibrosis, atherosclerosis, and various types of cancer. SR-302 serves as a key tool for elucidating the roles of DDR and p38 signaling pathways in disease progression and therapeutic intervention. -
p38/MAPK Inhibitor
LX-3 is a selective inhibitor of the p38 MAPK signaling pathway. It effectively modulates gene expression by reactivating silenced EGFP reporter genes associated with DNA methylation, including TNF, EGR1, LY6K, and ISG20. This reagent is valuable for studies investigating the roles of p38 MAPK in cellular processes and the impact of DNA methylation on gene regulation. -
p38 Inhibitor
p38α inhibitor 5 is a PROTAC-type ligand that specifically targets p38α MAP kinase. This compound is designed to facilitate the degradation of p38α, providing a valuable tool for studying the enzyme's role in cellular signaling and inflammation. It is suitable for applications in drug discovery and therapeutic research, particularly in the context of conditions associated with p38α dysregulation. -
p38 Inhibitor
Org 48762-0 is a selective p38 inhibitor, exhibiting a potent EC50 of 0.1 μM for p38α kinase. This compound demonstrates a high degree of specificity for both p38α and p38β over other kinases, allowing for targeted therapeutic interventions. Org 48762-0 effectively reduces lipopolysaccharide-induced TNFα release, making it a valuable tool in the study of inflammatory diseases. Its applications extend to researching conditions such as rheumatoid arthritis and Werner syndrome. -
p38α Inhibitor
Cyclocurcumin is a potent inhibitor of p38α, a key signaling molecule involved in inflammatory responses. It demonstrates significant antirheumatic, antivasoconstrictive, and antioxidant activities. This compound is valuable for research applications focused on inflammation, cardiovascular diseases, and oxidative stress. -
TAK1/p38α Inhibitor
PF-05381941 is a potent dual inhibitor of TAK1 and p38α, exhibiting IC50 values of 156 nM and 186 nM, respectively. This compound effectively modulates the MAPK signaling pathway, making it a valuable tool for investigating cellular responses to stress and inflammation. PF-05381941 is commonly utilized in research focused on cancer, autoimmune diseases, and other pathological conditions linked to dysregulated kinase activity. -
p38 MAPK Inhibitor
RO3201195 is a selective inhibitor of p38 MAPK, a key signaling molecule involved in inflammatory responses and cellular stress. This compound demonstrates potent inhibition of WS cell proliferation, with an IC50 value of 190 nM. RO3201195 is suitable for research applications aimed at understanding the role of p38 MAPK in various biological processes, including inflammation and cancer. -
Insulin/IGF-1/p38 MAPK Regulator
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 signaling pathway and p38 MAPK pathway, known for its ability to decrease reactive oxygen species and fat accumulation in Caenorhabditis elegans. This compound enhances β-oxidation while suppressing fatty acid synthesis via upregulation of SKN-1/NRF2 and downregulation of SREBP-1c transcription factors. 2-HIBA exhibits notable anti-aging and lipid-lowering properties, making it valuable for investigating metabolic diseases, including obesity and diabetes. Additionally, it serves as a renewable precursor for methacrylate production through 2-HIB-CoA mutase-mediated biosynthesis.
